Roche PD-L1+TIGIT combination fails in first-line treatment of stage III small cell lung cancer
- Why is Lung Cancer High in Non-Smoking Women?
- Is 16-Hour Intermittent Fasting Beneficial for Health?
- Molnupiravir Associated with SARS-CoV-2 Virus Unusual Mutations
- Why Don’t Some Cancer Immunotherapies Always Work as Expected?
- Potential Food Safety Blind Spots in Fast-Food Soda Machines
- Light Therapy Helps Clear Toxic Alzheimer’s Protein from the Brain
Roche PD-L1+TIGIT combination fails in first-line treatment of stage III small cell lung cancer
- Nearly 300 People Food Poisoning in Japanese 130-Year Restaurant
- FDA’s First Potential TIL Therapy Review Delayed: How to Understand FDA’s “Resource Constraints”?
- A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million
- Nuclear contaminated water: Japanese government paid bribes and corrected the IAEA report
- Top 20 Companies of Instruments and Medical Equipment In The World
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- How long can the patient live after heart stent surgery?
Roche PD-L1+TIGIT combination fails in first-line treatment of stage III small cell lung cancer.
On March 30, Roche announced that the phase III clinical trial (SKYSCRAPER-02) of tiragolumab + atezolizumab (TIGIT + PD-L1) in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) did not reach progression-free survival (SKYSCRAPER-02). PFS) primary endpoint.
Roche said that phase III clinical trials of PD-L1+TIGIT combination therapy for non-small cell lung cancer, esophageal squamous cell carcinoma and other cancers will continue as planned.
SKYSCRAPER-02 is a randomized, double-blind, placebo-controlled, global Phase III study to compare tiragolumab plus atezolizumab, chemotherapy as first-line therapy with atezolizumab and chemotherapy in 490 ES- Efficacy and safety in SCLC patients. The primary endpoints were overall survival (OS) and progression-free survival (PFS).
Tiragolumab is a TIGIT monoclonal antibody that has been granted breakthrough therapy designation by the FDA. By binding to TIGIT, it can block the interaction of TIGIT with a poliovirus receptor (PVR, or CD155) protein that can inhibit the body’s immune response, potentially enhancing the body’s immune response.
Atezolizumab (trade name: Taishengqi) is a PD-L1 immune checkpoint inhibitor independently designed and developed by Roche, which can directly interact with the PD-L1 ligand protein expressed on tumor cells and tumor-infiltrating immune cells.
Binds to block the interaction of PD-L1 with PD-1 and B7.1 receptors on immune cells, effectively activating T cells to recognize and kill tumor cells. Currently, the product has been approved for multiple indications, including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, triple negative breast cancer and urothelial cancer.
The combination of Tiragolumab and Tecentriq synergistically blocks TIGIT and PD-L1, activates T cells and enhances NK cell antitumor activity.
(source:internet, reference only)
Disclaimer of medicaltrend.org
